New to The Street’s TV Host Jane King talks with John Lai, CEO/President of PetVivo Holdings, Inc.’s (NASDAQ: PETV) (NASDAQ: PETVW) ($PETV) (“PetVivo”) about the Company. PetVivo manufactures, commercializes, and licenses innovative medical devices and pet therapeutics. John updates viewers about the Company’s patented product, Spryng with OsteoCushion Technology, a veterinarian’s tool to help pet owners manage their pets’ osteoarthritis and joint-related ailments. Today’s Veterinary Practice recently published a peer-reviewed article about Spryng’s efficacy. The Author, Dr. Tamara Grubb, DVM, Ph.D., DACVAA, wrote the article: “Select Drugs and Compounds for Canine Osteoarthritis Management,” which addresses osteoarthritis’ current treatments and the successfulness of new novel therapies. One new therapy mentioned is Spryng, which looks at the bone-on-bone causes of osteoarthritis, a front-line use treatment, and an effective alternative to dogs that cannot take NSAIDs (Non-steroidal anti-inflammation drugs). John believes Dr. Grubb will discuss Spryng and her article in upcoming veterinarian conferences. As of June 30, 2023, Spryng is now used in 450 clinical locations in 47 states, up from 50 in 2022. As Spryng becomes more widely known as an effective disruptive technology for treating dogs, horses, and cats with osteoarthritis, PETV sees upward growth. The on-screen QR code is available during the show; download or visit PetVivo Holdings, Inc. – https://petvivo.com/ & Spryng with OsteoCushion Technology – https://www.sprynghealth.com/.
To make sure you never miss a video from New to the Street, click here to subscribe: https://www.youtube.com/c/newtothestreettv
Follow New to the Street on Twitter: https://twitter.com/NewToTheStreet
Follow New to the Street on Facebook: https://www.facebook.com/newtothestreet/
Follow New to the Street on Instagram: https://www.instagram.com/newtothestreettv/
Follow New to the Street on Rumble: https://rumble.com/user/newtothestreet
About New to the Street: https://newtothestreet.com/
Subscribe to our Mailing List: https://mailchi.mp/ccd21b3e3fab/join-our-mailing-list